Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.

MLA

Graveno, Molly E., et al. “Venetoclax in Combination with Hypomethylating Agents or Low Dose Cytarabine for Relapsed and Refractory Acute Myeloid Leukemia.” Leukemia & Lymphoma, vol. 63, no. 7, July 2022, pp. 1645–50. EBSCOhost, https://doi.org/10.1080/10428194.2022.2042688.

APA

Graveno, M. E., Carulli, A., Freyer, C. W., Mangan, B. L., Nietupski, R., Loren, A. W., Frey, N. V., Porter, D. L., Gill, S. I., Hexner, E. O., Luger, S. M., Martin, M. E., McCurdy, S. R., Perl, A. E., Babushok, D. V., & Pratz, K. W. (2022). Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia. Leukemia & Lymphoma, 63(7), 1645–1650. https://doi.org/10.1080/10428194.2022.2042688

Chicago

Graveno, Molly E., Alison Carulli, Craig W. Freyer, Brendan L. Mangan, Robert Nietupski, Alison W. Loren, Noelle V. Frey, et al. 2022. “Venetoclax in Combination with Hypomethylating Agents or Low Dose Cytarabine for Relapsed and Refractory Acute Myeloid Leukemia.” Leukemia & Lymphoma 63 (7): 1645–50. doi:10.1080/10428194.2022.2042688.